Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Sabino De PlacidoSandro Pignata

Abstract

Topotecan is an active second-line treatment for advanced ovarian cancer. Its efficacy as consolidation treatment after first-line standard chemotherapy is unknown. To investigate whether topotecan (1.5 mg/m(2) on days 1 through 5, four cycles, every 3 weeks) prolonged progression-free survival (PFS) for patients responding to standard carboplatin (area under the curve 5) and paclitaxel (175 mg/m(2) administered as a 3-hour infusion in six cycles; CP), a multicenter phase III study was performed with an 80% power to detect a 50% prolongation of median PFS. Patients were registered at diagnosis and randomized after the end of CP. Two hundred seventy-three patients were randomly assigned (topotecan, n = 137; observation, n = 136), with a median age of 56 years. Stage at diagnosis was advanced in three fourths of patients (stage III in 65% of patients; stage IV in 10%); after primary surgery, 46% had no residual disease and 20% were optimally debulked. After CP, 87% reached a clinical complete response, and 13% achieved a partial response. Neutropenia (grade 3/4 in 58% of the patients) and thrombocytopenia (grade 3 in 21%; grade 4 in 3%) were the most frequent toxicities attributed to topotecan. There was no statistically signific...Continue Reading

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ten Bokkel HuininkJ F Heron
Apr 29, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J S BerekP H Willemse
May 4, 2000·Journal of the National Cancer Institute·W P McGuire
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P NeijtH C van Houwelingen
Apr 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M GoreS Z Fields
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert E BristowF J Montz
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mahesh A VariaUNKNOWN Gynecologic Oncology Group
Sep 4, 2003·Journal of the National Cancer Institute·Andreas du BoisUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Dec 24, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen J FreedlandMartha K Terris

❮ Previous
Next ❯

Citations

May 29, 2012·Medical Oncology·Achuta Kumar Guddati
Dec 7, 2013·ACS Applied Materials & Interfaces·Mohammad H El-DakdoukiXuefei Huang
Feb 25, 2009·Nature Reviews. Cancer·Timothy A YapStan B Kaye
Feb 22, 2013·Nature Reviews. Cancer·Emma KippsStan B Kaye
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A Bookman
Oct 13, 2010·Journal of the National Cancer Institute·William P McGuire
Feb 24, 2006·Current Opinion in Obstetrics & Gynecology·Daynelle D Dearnley, D Scott McMeekin
Feb 22, 2012·Clinical Obstetrics and Gynecology·Michael A Bookman
Dec 14, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M A Bookman
Apr 21, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A Du Bois, J Pfisterer
Feb 1, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S-J LeeD-S Bae
May 18, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A H Comander, S A Cannistra
Apr 11, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M A Bookman
Mar 2, 2012·Gynecologic and Obstetric Investigation·Yukihisa MinagawaJunzo Kigawa
Dec 18, 2008·Future Oncology·Dirk O BauerschlagJakobus Pfisterer
Apr 29, 2014·Lancet·Gordon C JaysonJonathan A Ledermann
Dec 30, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Michael A Bookman
Jun 24, 2014·Expert Review of Anticancer Therapy·Cristina FalciPierfranco Conte
Mar 29, 2012·Expert Opinion on Drug Delivery·Payam ZahediChristine Allen
Sep 4, 2008·Expert Opinion on Emerging Drugs·Toru Sugiyama, Ikuo Konishi
Jul 8, 2010·Expert Opinion on Emerging Drugs·Domenica LorussoGiovanni Scambia
Apr 7, 2010·Expert Opinion on Investigational Drugs·Liz Y HanStan B Kaye
Feb 24, 2009·Current Medical Research and Opinion·Jalid Sehouli, Gülten Oskay-Ozcelik
Nov 10, 2012·Critical Reviews in Oncology/hematology·Bradley J MonkIvor Benjamin
Sep 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michael A Bookman
Nov 12, 2015·Critical Reviews in Oncology/hematology·Nicoletta ColomboGiovanni Scambia
Jan 9, 2010·Gynecologic Oncology·Valentina GuarneriPier Franco Conte
Oct 20, 2009·Gynecologic Oncology·Paul SabbatiniAlexia Iasonos
Oct 2, 2009·Lancet·Bryan T HennessyMaurie Markman
Sep 22, 2009·Critical Reviews in Oncology/hematology·Domenica LorussoGiovanni Scambia
Dec 17, 2015·Asia-Pacific Journal of Clinical Oncology·Jeffrey GohSally Baron-Hay
Jun 7, 2007·Mayo Clinic Proceedings·Giovanni D AlettiLynn C Hartmann
Mar 10, 2009·Journal of Surgical Oncology·Sokbom KangSang-Yoon Park

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.